Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tepezza
Biotech
Viridian’s Tepezza rival racks up another ph. 3 win
Viridian is preparing to file for FDA approval next year and challenge Amgen for a blockbuster market.
Nick Paul Taylor
May 5, 2026 8:00am
Viridian’s Tepezza rival scores ph. 3 win, but investors unsure
Mar 30, 2026 10:11am
Sling's oral Tepezza rival hits goal in thyroid eye disease
Jan 14, 2025 8:16am
Viridian eye disease phase 3 hits, advancing push to rival Amgen
Sep 10, 2024 8:10am
Acelyrin loses interest in izokibep, lays off 3rd of staff
Aug 13, 2024 4:00pm
Acelyrin's proof-of-concept TED data cement Amgen challenge
Mar 20, 2024 7:00am